Photo by liubovilchuk from unsplash
Bullous pemphigoid (BP), the by far most frequent autoimmune blistering skin disease (AIBD), is immunopathologically characterized by autoantibodies against the two hemidesmosomal proteins BP180 (collagen type XVII) and BP230 (BPAG1… Click to show full abstract
Bullous pemphigoid (BP), the by far most frequent autoimmune blistering skin disease (AIBD), is immunopathologically characterized by autoantibodies against the two hemidesmosomal proteins BP180 (collagen type XVII) and BP230 (BPAG1 or dystonin). Several comorbidities and potentially disease‐inducing medication have been described in BP, yet a systematic analysis of these clinically relevant findings and autoantibody reactivities has not been performed.
Keywords:
serum autoantibody;
bullous pemphigoid;
autoantibody reactivity;
pemphigoid associated;
pemphigoid;
reactivity bullous
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!